表紙:ブルーム症候群治療の世界市場-2023年~2030年
市場調査レポート
商品コード
1352118

ブルーム症候群治療の世界市場-2023年~2030年

Global Bloom Syndrome Treatment Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
ブルーム症候群治療の世界市場-2023年~2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界のブルーム症候群治療市場は近年成長を遂げています。ブルーム症候群は、ブルーム・トレ・マチェック症候群または先天性毛細血管拡張性紅斑としても知られています。ブルーム症候群の患者は通常、出生時から身長・体重ともに人口の97%より小さく、成人期に身長が1メートル以上になることは稀です。

ブルーム症候群の治療には、無防備な日光浴を避け、必要に応じて言語療法、作業療法、理学療法を行い、気道の粘液除去を助ける補助器具を使用し、成長ホルモンを使用します。ブルーム症候群には治療法はありませんが、上記の治療法は病気の経過観察に役立ちます。

認知度の向上と疾病管理の改善により、新規治療薬に対する需要の増加、早期診断、治療選択肢の技術的進歩が、世界のブルーム症候群治療市場を牽引すると予想される主な要因です。

ダイナミクス

新規治療薬の需要増加がブルーム症候群治療市場の成長を牽引

ブルーム症候群を完治させる治療法は存在しませんが、ブルーム症候群を管理するための治療薬は数多く存在します。ブルーム症候群の治療において、新規治療薬への需要が高まっています。特にブルーム症候群のような稀で複雑な疾患に対しては、より効果的な新しい治療法が常に必要とされています。新規治療薬は、患者により良い結果をもたらし、生活の質を改善するという潜在的な利益をもたらします。

例えば、2022年3月22日、ペンシルバニア大学の希少疾患センター(ODC)は、ブルーム症候群助成金プログラムを発表しました。ブルーム症候群の知識や治療法、治療薬の開発を進歩させる助成金の申請を求めています。

医学的知識と技術が進歩するにつれて、研究者はブルーム症候群の根本的なメカニズムをより深く理解するようになります。この理解により、新規治療薬の臨床試験や、ブルーム症候群のような遺伝性疾患に対する潜在的な治療法を含む標的療法や個別化治療の開発に新たな機会が開かれます。

認知度の向上と管理の改善もブルーム症候群治療市場の成長を促す

啓発キャンペーンはブルーム症候群の管理を強化し、医療従事者の教育改善はブルーム症候群の早期診断にもつながります。早期発見と診断により、タイムリーな介入と適切な医療が可能になり、患者の転帰とQOLが改善する可能性があります。このため、医療提供者は、ブルーム症候群のような希少遺伝性疾患の管理に精通した専門のクリニックやセンターの設立を促しています。

例えば、2023年3月1日、希少疾病の日(Rare Disease Day 2023)にちなんで、ブルーム症候群協会は、新しいブルーム症候群協会のロゴ入りTシャツを用いた募金啓発キャンペーンを開始しました。その主な目的は、ブルーム症候群を含むすべての希少疾患の認知を広め、ブルーム症候群に苦しむすべての家族を教育し支援することにあります。

ブルーム症候群の認知度が高まれば、臨床試験や研究資金の増加、官民双方からの投資を呼び込むことができます。より多くの資源が利用できるようになれば、標的療法や遺伝子に基づく治療法を含む新しい治療法の開発に対する需要が高まり、その結果、ブルーム症候群の管理がより良く強化されることになります。

治療に伴う副作用が市場の成長を妨げる

ブルーム症候群の患者はがんを発症するリスクが高いため、ブルーム症候群の場合、がんの発症を防ぐために治療を慎重に行わなければなりません。もし治療法が間違っていれば、人々はより多くの影響を受け、より早い段階でがんを発症する危険性があります。

重篤な副作用や頻度の高い副作用を伴うブルーム症候群の治療は、規制当局の承認プロセスにおいて課題に直面することになります。規制機関は患者の安全性と有効性を優先するため、副作用の多発はブルーム症候群治療薬の市場承認を遅らせたり、妨げたりする可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 革新的な治療薬に対する需要の増加
      • 認知度の向上と管理の改善
    • 抑制要因
      • 治療に伴う副作用
    • 機会
      • 治療選択肢の技術的進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 治療タイプ別

  • 抗生物質
  • 陽子線治療
  • 遺伝カウンセリング
  • 言語療法
  • 作業療法
  • 理学療法
  • その他

第8章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Allergan Plc
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

第12章 付録

目次
Product Code: PH6875

Overview

The global bloom syndrome treatment market witnessing growth in recent years. Bloom syndrome is also known as Bloom-Torre-Machacek syndrome or congenital telangiectatic erythema. People with bloom syndrome are usually smaller than 97 percent of the population in both height and weight from birth, and they rarely exceed 5 feet tall in adulthood.

The treatment of bloom syndrome includes avoidance of unprotected sun exposure, speech therapy, occupational therapy, or physical therapy as needed, use of assistive devices to help clear mucus from airways and use of growth hormones. Overall, the bloom syndrome has no cure but the above mentioned treatments are helpful for the monitoring of the disease.

Owing to the increasing awareness and improved disease management, increasing demand for novel therapeutics, early diagnosis, and technological advancements in treatment options are the major factors expected to drive the global bloom syndrome treatment market.

Dynamics

Increasing Demand for Novel Therapeutics Drive the Growth of the Bloom Syndrome Treatment Market

There is no cure for the bloom syndrome, but there are many therapeutics for the management of the bloom syndrome. There is an increasing demand for the novel therapeutics in management of the bloom syndrome. There is a constant need for new and more effective treatments, especially for rare and complex conditions like bloom syndrome. Novel drugs offer the potential benefits of providing better outcomes and improved quality of life for patients.

For instance, on March 22, 2022, the Orphan Disease Center (ODC) at the University of Pennsylvania announced the Bloom Syndrome Grant Program. They are seeking grant applications that progress the knowledge or the development of treatments and/or cures for bloom syndrome.

As medical knowledge and technologies advance, researchers gain a deeper understanding of the underlying mechanisms of bloom syndrome. This understanding opens up new opportunities on clinical trials for novel therapeutics and for developing targeted therapies and personalized treatments, including potential treatments for genetic disorders like bloom syndrome.

Increasing Awareness and Improved Management Also Drives the Growth of the Bloom Syndrome Treatment Market

Awareness campaigns enhance the management of the bloom syndrome and improved education among healthcare professionals can also lead to earlier diagnosis of bloom syndrome. Early detection and diagnosis allow for timely intervention and appropriate medical care, potentially improving patient outcomes and quality of life. This prompts healthcare providers to establish dedicated clinics or centers with expertise in managing rare genetic disorders like bloom syndrome.

For instance, on March 1, 2023, in honor of Rare Disease Day 2023, the bloom syndrome association launched a fundraising awareness campaign featuring t-shirts with the new Bloom Syndrome Association logo. The main goal is to help spread awareness of all rare diseases, including bloom syndrome, and to educate and support all families who are suffering from bloom syndrome.

Increased awareness of bloom syndrome can attract increased clinical trials and research funding and investments from both public and private sectors. As more resources become available, there is a higher demand for new treatment options, including targeted therapies and gene-based treatments, being developed, which results in the better and enhanced management of bloom syndrome.

Side Effects Associated with Treatment Will Hamper the Growth of the Market

People with bloom syndrome are at a high risk of developing cancer and thus, treatment must be done carefully in order to prevent cancer from developing in case of bloom syndrome. If treatment measures go wrong, people will be affected more and be at risk of developing cancer in earlier stages.

The treatment of bloom syndrome associated with severe or frequent adverse effects leads to facing challenges during the regulatory approval process. Regulatory agencies prioritize patient safety and efficacy, and a high incidence of adverse effects could delay or prevent market approval of the bloom syndrome therapeutics.

Segment Analysis

The global bloom syndrome treatment market is segmented based on treatment type, end-user, and region.

The Antibiotics from the Treatment Segment Accounted for Approximately 35.7% of the Bloom Syndrome Market Share

Antibiotics play a crucial role in the management of the bloom syndrome. Bloom syndrome causes growth changes, skin rashes, and skin infections as they are extremely sensitive to sunlight and are at higher risk of developing many cancers. Moreover, there is no cure for this syndrome, but healthcare providers use antibiotics for the management and regular cancer screenings to help keep people with bloom syndrome as healthy as possible.

Appropriate antibiotics for gastrointestinal and respiratory tract bacterial infections are commonly helpful in the management of patients with this type of syndrome. Antibiotics are sometimes used prophylactically in individuals with bloom syndrome to prevent infections before they occur. Prophylactic antibiotic treatment aims to reduce the risk of infection in those who are at high risk due to their condition.

Antibiotics are part of the supportive care measures used to manage the symptoms and complications associated with bloom syndrome, helping to improve the overall quality of life for affected individuals. Hence, antibiotics are expected to hold the largest market share for the management of bloom syndrome.

Geographical Penetration

North America Accounted for Approximately 39.4% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Advanced Healthcare Infrastructure

North America is home to many leading pharmaceutical and biotechnology companies that have a strong presence in the region. These companies have robust research and development activities related to the bloom syndrome allowing them to introduce innovative treatments and therapies. Their market dominance and extensive distribution networks contribute to the region's substantial market share.

North America has a highly developed and advanced healthcare infrastructure, including hospitals, clinics, research centers, and academic institutions. This infrastructure facilitates clinical trials, regulatory approvals, and the adoption of new medical advancements for the management of bloom syndrome. Hence, driving the growth of the bloom syndrome treatment market.

Competitive Landscape

The major global players in the bloom syndrome treatment market include Allergan plc, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, and Sun Pharmaceutical Industries Ltd. Among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global bloom syndrome treatment market. The pandemic resulted in delays and interruptions in clinical trials across various therapeutic areas, including rare diseases like bloom syndrome. Clinical trials for potential bloom syndrome treatments might have faced challenges in patient recruitment, monitoring, and data collection due to restrictions on travel, social distancing measures, and damaged healthcare facilities.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global bloom syndrome treatment market. The conflict results in the disruption of the clinical trials and the supply chain disruption such as antibiotics and other therapeutics. This results in an impact on the overall global bloom syndrome treatment market.

By Treatment Type

  • Antibiotics
  • Proton Beam Therapy
  • Genetic Counseling
  • Speech Therapy
  • Occupational Therapy
  • Physical therapy
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global bloom syndrome treatment market segmentation based on treatment type, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of bloom syndrome treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global bloom syndrome treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End-User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Innovative Therapeutics
      • 4.1.1.2. Rising Awareness and Improved Management
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements in Therapeutic Options
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Antibiotics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Proton Beam Therapy
  • 7.4. Genetic Counseling
  • 7.5. Speech Therapy
  • 7.6. Occupational Therapy
  • 7.7. Physical therapy
  • 7.8. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Spain
      • 9.3.5.5. Italy
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Allergan Plc *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Merck & Co., Inc.
  • 11.3. Pfizer Inc.
  • 11.4. GlaxoSmithKline plc
  • 11.5. Abbott Laboratories
  • 11.6. F. Hoffmann-La Roche Ltd.
  • 11.7. Teva Pharmaceutical Industries Ltd.
  • 11.8. Sanofi
  • 11.9. Novartis AG
  • 11.10. Sun Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us